Skip to main content
Premium Trial:

Request an Annual Quote

DeCode, Spending More on Clinical Trials, Reports Ballooning Losses, Smaller Revenues in Q3

NEW YORK, Nov. 3 (GenomeWeb News) - DeCode Genetics yesterday reported reduced revenues and a gaping net loss for the third quarter of the year, mainly related to higher R&D costs for its drug-development programs.


The Icelandic phamacogenomics company booked $11 million in revenues for the quarter ended Sept. 30, down from $12.8 million during the same period last year. Part of this decrease resulted from deferred milestone payments made by Merck, DeCode said in a statement.


R&D expenses soared to $6.5 million from $250,000 during the year-ago period, mainly the result of a recently completed phase IIa clinical trial and preparations for upcoming clinical studies. Also, DeCode's R&D costs were especially low a year ago because of a one-time non-cash reversal of accrued license fees.


DeCode's net loss climbed to $12.5 million, or $.23 per share, from $1.3 million, or $.03 per share, for the same quarter last year.


As of Sept. 30, DeCode had $215.2 million in cash and short-term investments.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.